News_About us_Chongqing Huapont Shengchem Pharm. Co., Ltd.

Huapont Team to Participate CPhI Worldwide 2024 (October 8-10, Booth No.: 2B42)

2024/04/27

Huapont Team to Participate CPhI Worldwide 2024 (October 8-10, Booth No.: 2B42)

Huapont will be actively participating in CPhI Worldwide 2024 (Booth No.: 2B42). This prestigious event, aiming on serving a global community – advancing human health, will take place from October 8 to October 10, 2024, in Milan, Italy.

View More →

Huapont will be actively participating in CPhI Worldwide 2024 (Booth No.: 2B42). This prestigious event, aiming on serving a global community – advancing human health, will take place from October 8 to October 10, 2024, in Milan, Italy.

Huapont Team to Participate CPhI China 2024 (June 19-21, Booth No.: W3E52b).

2024/04/26

Huapont Team to Participate CPhI China 2024 (June 19-21, Booth No.: W3E52b).

Huapont will be actively participating in CPhI China 2024 (Booth No.: W3E52b). This prestigious event, turning local connections into endless opportunity, will take place from June 19 to June 21, 2024, in Shanghai, China.

View More →

Huapont will be actively participating in CPhI China 2024 (Booth No.: W3E52b). This prestigious event, turning local connections into endless opportunity, will take place from June 19 to June 21, 2024, in Shanghai, China.

Huapont Team to Participate API China 2023 (May 15-17, Booth No.: 1.2W03)

2024/04/25

Huapont Team to Participate API China 2023 (May 15-17, Booth No.: 1.2W03)

Huapont will be actively participating in API China 2024 (Booth No.: 1.2W03). This prestigious event, Asia’s leading pharmaceutical show for trading, knowledge sharing and networking, spaning all industry sectors along the pharmaceutical supply chain, will take place from May 15-17, 2024, in Shanghai, China.

View More →

Huapont will be actively participating in API China 2024 (Booth No.: 1.2W03). This prestigious event, Asia’s leading pharmaceutical show for trading, knowledge sharing and networking, spaning all industry sectors along the pharmaceutical supply chain, will take place from May 15-17, 2024, in Shanghai, China.

Huapont Team to Participate DCAT Week 2024 (March 18-21)

2024/02/26

Huapont Team to Participate DCAT Week 2024 (March 18-21)

Huapont will be actively participating in DCAT Week 2024. This prestigious event, known for its high-level business meetings and networking opportunities, will take place from March 18 to March 21, 2024, in New York.

View More →

Huapont will be actively participating in DCAT Week 2024. This prestigious event, known for its high-level business meetings and networking opportunities, will take place from March 18 to March 21, 2024, in New York.

Huapont Would Attend DCAT, March 20-23, 2023

2023/02/21

Huapont Would Attend DCAT, March 20-23, 2023

DCAT Week

View More →

DCAT Week

Huapont is awarded with CEP certificate of Tretinoin

2022/09

Huapont is awarded with CEP certificate of Tretinoin

Huapont Shengchem obtained Ruxolitinib Phosphate WC certificate

2022/05/27

Huapont Shengchem obtained Ruxolitinib Phosphate WC certificate

Huapont Shengchem is one of leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ruxolitinib Phosphate (CAS Number: 1092939-17-7) API. DMF (No. 029480）has been submitted to US FDA and it is available for reference. In early time of this month, Huapont shengchem GMP management system has been inspected by Chongqing Municiple Drug Administration. Huapont Shengchem passed the inspection and obtained Ruxolitinib Phosphate WC certificate (Written confirmation for active substances exported to EU). Label of JAKAFI® (Manufactured by Incyte Corporation) showes Ruxolitinib Phosphate tablet is a kinase inhibitor indicated for treatment of: (1) intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults; (2) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; (3)steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; (4) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. A topical use drug product with new preparation (cream) was newly approved by US FDA in 2021.

View More →

Huapont Shengchem is one of leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ruxolitinib Phosphate (CAS Number: 1092939-17-7) API. DMF (No. 029480）has been submitted to US FDA and it is available for reference. In early time of this month, Huapont shengchem GMP management system has been inspected by Chongqing Municiple Drug Administration. Huapont Shengchem passed the inspection and obtained Ruxolitinib Phosphate WC certificate (Written confirmation for active substances exported to EU). Label of JAKAFI® (Manufactured by Incyte Corporation) showes Ruxolitinib Phosphate tablet is a kinase inhibitor indicated for treatment of: (1) intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults; (2) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; (3)steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; (4) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. A topical use drug product with new preparation (cream) was newly approved by US FDA in 2021.

Huapont was awarded <Certificate of Intellectual Property Management System>

2021/12/22

Huapont was awarded <Certificate of Intellectual Property Management System>

　　On March 1, 2013, was published. It helped raising awareness of intellectual property right, innovation and furtherly enhancing innovation capacity. Recently, intellectual property management system of Huapont was inspected and approved by Zhongbiaotong International Certification (Shenzhen) Co., Ltd. Huapont was awarded .

View More →

　　On March 1, 2013, was published. It helped raising awareness of intellectual property right, innovation and furtherly enhancing innovation capacity. Recently, intellectual property management system of Huapont was inspected and approved by Zhongbiaotong International Certification (Shenzhen) Co., Ltd. Huapont was awarded .

Huapont Life Sciences ranked top 100 private enterprises in Chongqing

2021/10/28

Huapont Life Sciences ranked top 100 private enterprises in Chongqing

On October 9,2021, “2021 Chongqing Top 100 Private Enterprises Summit” was hold in Chongqing, hosted by Chongqing Federation of Industry and Commerce,

View More →

On October 9,2021, “2021 Chongqing Top 100 Private Enterprises Summit” was hold in Chongqing, hosted by Chongqing Federation of Industry and Commerce,

Huapont Pharm. has awarded with “2020 Benchmark Intelligent Manufacturer of Chongqing”

2020/09/15

Huapont Pharm. has awarded with “2020 Benchmark Intelligent Manufacturer of Chongqing”

On September 15th, ceremony of “2020 Benchmark Intelligent Manufacturer of Chongqing” was held successfully at The Third Industrial and Intelligent Manufacturing Summit Forum of Smart China Expo Online 2020.

View More →

On September 15th, ceremony of “2020 Benchmark Intelligent Manufacturer of Chongqing” was held successfully at The Third Industrial and Intelligent Manufacturing Summit Forum of Smart China Expo Online 2020.

TDMF for Moxifloxacin HCl is approved by Taiwan FDA

2020/04

TDMF for Moxifloxacin HCl is approved by Taiwan FDA

US-DMF of Bendamustine HCl was approved by FDA (allied dosage was approved).

2020/04

US-DMF of Bendamustine HCl was approved by FDA (allied dosage was approved).

Moxifloxacin HCl obtained the GMP certificate issued by PMDA.

2020/02

Moxifloxacin HCl obtained the GMP certificate issued by PMDA.

Roflumilast, Calcipotriol Monohydrate, Alitretinoin, bepotastine besilate, Bexarotene, Bendamustine Hydrochloride and Bendamustine Hydrochloirde Monohydrate obtained W/C (Written Confirmation).

2020/01

Roflumilast, Calcipotriol Monohydrate, Alitretinoin, bepotastine besilate, Bexarotene, Bendamustine Hydrochloride and Bendamustine Hydrochloirde Monohydrate obtained W/C (Written Confirmation).

Tretinoin, Tazarotene, Calcipotriol, Acrivastine, Levocetirizine Hydrochloride, Dapsone, Naftifine Hydrochloride, Olopatadine Hydrochloride and Moxifloxacin Hydrochloride obtained W/C (Written Confirmation).

2019/07

Tretinoin, Tazarotene, Calcipotriol, Acrivastine, Levocetirizine Hydrochloride, Dapsone, Naftifine Hydrochloride, Olopatadine Hydrochloride and Moxifloxacin Hydrochloride obtained W/C (Written Confirmation).

Isotretinoin and Acitretin obtained renewal W/C (Written Confirmation).

2019/04

Isotretinoin and Acitretin obtained renewal W/C (Written Confirmation).

Alitretinoin obtained the GMP certificate from South Korean FDA.

2019/01

Alitretinoin obtained the GMP certificate from South Korean FDA.

The manufacturing site is informed approved by the US-FDA inspection.

2018/09

The manufacturing site is informed approved by the US-FDA inspection.

DMF of Isotretinoin is submitted to Saudi FDA.

2017/11

DMF of Isotretinoin is submitted to Saudi FDA.

US-DMF of Isotretinoin is listed in FDA’s reference available list.

2017/09

US-DMF of Isotretinoin is listed in FDA’s reference available list.

语言版本

HUAPONT SHENGCHEM

2024/04/27

2024/04/26

2024/04/25

2024/02/26

2023/02/21

2022/09

2022/05/27

2021/12/22

2021/10/28

2020/09/15

2020/04

2020/04

2020/02

2020/01

2019/07

2019/04

2019/01

2018/09

2017/11

2017/09

友情链接

地址版权

地址版权手机